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Abstract
Background: Tuberculosis (TB) is a common opportunistic infection after kidney transplantation (KT). The
QuantiFERON-TB-Gold In-Tube test (QFT) is widely used for assessing latent TB; however, it is currently unclear
whether the pre-KT QFT of the recipient and donor can predict post-KT TB.
Methods: We retrospectively reviewed patients who received KT between January 2009 and December 2015 at
Seoul National University Hospital. The QFT was performed in 458 KT recipients and 239 paired living donors, and
138 KT recipients underwent both the QFT and tuberculin skin test (TST). After excluding 12 patients diagnosed as
having clinically latent TB, we evaluated whether the QFT of the recipient and donor was predictive for new-onset
active TB after KT.
Results: The QFT was positive in 101 (22.1%) recipients and associated with clinically latent TB before KT (P < 0.05).
However, agreement between the TST and QFT was poor (κ = 0.327). Post-KT TB occurred in 1 of 95 recipients with
a positive QFT, and 2 cases of TB occurred among 351 patients with a negative or indeterminate QFT. The
incidence of TB was 242 cases/100,000 person-years among 446 KT recipients with a median follow-up of 30.
2 months. The QFT of recipients could not predict post-KT TB in Poisson regression analysis (relative risk [RR], 1.847;
95% confidence interval [CI], 0.168–20.373; P = 0.616). Of 234 living donor-recipient pairs, the QFT of the recipient
(RR, 5.012; 95% CI, 0.301–83.430; P = 0.261) and QFT of the donor (RR, 1.758; 95% CI, 0.106–29.274; P = 0.694) could
not predict post-KT TB.
Conclusion: The QFT of recipients or living donors pre-KT cannot predict the short-term development of post-KT
TB in an intermediate TB-burden country.
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Background
Tuberculosis (TB) is a common opportunistic infection
after transplantation. The incidence of TB among trans-
plant recipients is 20–74 times higher than that in the
general population [1], and TB after transplantation can
adversely affect graft viability and patient survival [2].
The most common cause of TB in kidney transplant-
ation (KT) recipients is reactivation of latent TB. There-
fore, screening and treating active or latent TB in all
transplant candidates is widely recommended [2–4].
History taking, physical examination, and chest radiog-
raphy should be performed to assess for TB before trans-
plantation. To make a diagnosis of latent TB, the
tuberculin skin test (TST) or interferon (IFN)-γ release
assay (IGRA) is used. However, the Korean guidelines for
TB, which were revised in 2014, recommend the use of
IGRA alone or TST combined with IGRA for diagnosing
latent TB in patients with end-stage renal disease (ESRD),
because TST may yield a false positive result in those with
a previous Bacillus Calmette-Guérin (BCG) vaccination or
a false negative in patients with ESRD [5, 6].
The TB burden of South Korea is decreasing, but the
country is still classified as having an intermediate TB
burden, with an annual TB incidence of 86/100,000
person-years in 2015 [7] and a TB incidence after KT of
0.283 cases/100 patient-years in a previous study [8]. The
QuantiFERON-TB-Gold In-Tube test (QFT) (Cellestis
Ltd., Carnegie, Victoria, Australia) was introduced at our
center in 2009. However, because the significance of QFT
results in immunosuppressed patients was not sufficiently
validated, we did not administer anti-TB medications to
patients based on the results of QFT alone, unless there
was evidence of clinically latent TB, which includes abnor-
mal chest radiograph findings or a history of TB without
complete anti-TB medication and recent close contact
with individuals with active TB. The predictive ability of
the QFT for post-KT TB in KT recipients is still unclear;
therefore, we investigated the efficacy of using the QFT
pre-KT in recipients and donors to predict the subsequent
development of TB after KT.
Methods
Study population
This study was a retrospective, single-center study. Nine
hundred seventy-seven cases of KT were performed
from January 1, 2009 to December 31, 2015 at Seoul
National University Hospital. KT recipients who under-
went the QFT were enrolled in this study. The associ-
ation between clinical latent TB and QFT or TST was
analyzed with the recipient who underwent the QFT and
TST. The predictability of the QFT of recipients and
donors for post-KT TB was analyzed after excluding
recipients with isoniazid prophylaxis. This study was
approved by our institutional review board (H-1310-
069-527), and the need for informed consent was waived
because of its retrospective design.
Data collection
The demographic characteristics and laboratory results of
KT recipients and donors were retrospectively obtained
from medical records. Age, gender, body weight, KT time,
donor type, donor age, donor gender, comorbid disease
including a history of TB infection and previous BCG
vaccination, post-transplant medications including immu-
nosuppressants, and laboratory data including QFT and
chest radiographs were collected. TB development after
KT was determined by microbiological confirmation and
the initiation of anti-TB medication. Clinical latent TB
was defined as (1) an inadequate history of anti-TB medi-
cation with a history of TB infection or an inactive TB
lesion on a chest radiograph, (2) close contact with a
person with pulmonary TB within the past year, and (3)
recent conversion of the TST to a positive status [9, 10].
Laboratory testing (IGRAs and TST)
Peripheral blood samples for the QFT were collected,
transferred to the laboratory, and processed within 3 h
according to the manufacturer’s instructions [11]. The
QFT results were classified as positive, negative, or
indeterminate, as previously described : positive if the
response to the specific antigens was ≥ 0.35 IU/mL,
regardless of the value of the positive control; negative if
the response to the specific antigens was < 0.35 IU/mL and
the IFN-γ level of the positive control was ≥ 0.5 IU/mL;
and indeterminate if both antigen-stimulated samples
were < 0.35 IU/mL and the value of the positive control
was < 0.5 IU/mL [12].
TST was performed by trained nurses within 1 week
after the QFT. Two tuberculin units of purified protein
derivative RT23 (Statens Serum Institute, Copenhagen,
Denmark) were injected intradermally on the volar side
of the forearm contralateral to the patient’s vascular
access (the Mantoux technique). The diameter of indur-
ation was measured 48 h after administration. The test
was considered positive if the diameter of induration
was ≥10 mm.
Statistical analysis
Categorical variables are presented as frequencies, and
continuous values are expressed as the mean ± standard
deviation. Proportions were compared using the chi-
square test, and continuous variables were compared
using the Student t-test. Poisson regression models
were used to estimate the relative risk (RR) and 95%
confidence interval (CI). A P-value <0.05 was consid-
ered statistically significant. All statistical analyses were
conducted using SPSS, version 22.0 (SPSS Inc.,
Chicago, IL).
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Results
Characteristics of the study population
The QFT was performed in 458 KT recipients (living
donor KT, 303; deceased donor KT, 155). Baseline char-
acteristics for the 458 recipients are shown in Table 1.
Patients’ mean age was 44.5 ± 15.4 years, and 300
(65.4%) were men. Twenty-one (4.6%) KT recipients had
a TB history, and all of them received adequate anti-TB
medication. Seventeen (3.7%) patients showed radiologic
evidence of previous TB, such as a calcified granuloma
or nodule (six patients), nodular opacity (8), and other
(3). However, 12 had not received adequate anti-TB
medication. Hypertension and diabetes were found in
377 (82.3%) and 110 (24.0%) patients, respectively.
Of 458 recipients with QFT results, 239 matched
living donors underwent the QFT. Clinical information
for the 239 paired recipients and living donors are shown in
Table 1. The mean age of the 239 recipients was 40.6 ±
16.1 years, and 157 (65.7%) were men. Seven (2.9%) had a
history of TB, and seven (2.9%) had inactive TB lesions on a
chest radiograph. The mean age of the 239 paired donors
was 45.9 ± 10.2 years, and 103 (43.1%) were men. Nineteen
(7.9%) donors had a history of TB, and 14 (5.9%) had in-
active TB lesions on a chest radiograph. Nineteen (7.9%) do-
nors had hypertension and 1 (0.4%) had diabetes mellitus.
Association of the diagnostic tests with clinically latent
TB infection
Of 458 recipients with QFT results, 138 also underwent
TST. The association of the diagnostic tests with
clinically latent TB was analyzed in 138 recipients who
underwent both tests (Table 2). Among 458 KT recipi-
ents with QFT results, 101 (22.1%) showed positive QFT
results, and a positive QFT result was associated with
radiologic evidence of previous TB (P < 0.001), a history
of previous TB (P < 0.05), and overall clinically latent TB
(P < 0.05).
Among 138 KT recipients who underwent QFT and
TST, the QFT tended to be associated with a chest
radiographic lesion, history of previous TB, and clinically
latent TB despite the absence of statistical significance
(Table 2). However, TST was not associated with clinic-
ally latent TB, and agreement between TST and QFT in
these 138 KT recipients was poor (κ = 0.327).
Observations on the development of TB after KT
After excluding 12 patients with clinically latent TB who
received isoniazid treatment, 446 cases were analyzed to
determine whether QFT was predictive for post-KT TB de-
velopment. The predictive ability of QFT for post-KT TB
development was also analyzed in 234 living donor-
recipient pairs after excluding 5 recipients with clinically
latent TB who received isoniazid treatment (Fig. 1a and b).
Active TB occurred in 3 of 446 KT recipients, 1 with a
positive QFT result and 2 with negative or indeterminate
results, at a median follow-up of 30.2 months (Fig. 1a).
The incidence of TB was estimated to be 0.242/100
person-years; 0.360/100 person-years in the positive
QFT group and 0.208/100 person-years in the negative
or indeterminate QFT group (Table 3).
Table 1 Baseline clinical characteristics of study population
Recipients (n = 458) Recipient-donor pairs (n = 239)
Recipients (n = 239) Donors (n = 239)
Age, year (± SD) 44.5 ± 15.4 40.6 ± 16.1 45.9 ± 10.2
Male gender 300 (65.5) 157 (65.7) 103 (43.1)
History of TB infection 21 (4.6) 7 (2.9) 19 (7.9)
History of close contact with active TB 0 (0.0) 0 (0.0) 0 (0.0)
Abnormal chest radiography 17 (3.7) 7 (2.9) 14 (5.9)
History of adequately treated TB 5 (1.1) 2 (0.8) 1 (0.4)
History of untreated TB 12 (2.6) 5 (2.1) 13(5.4)
Underlying disease
Hypertension 377 (82.3) 184 (77.0) 19 (7.9)
Diabetes mellitus 110 (24.0) 49 (20.5) 1 (0.4)
History of malignancy 32 (7.0) 9 (3.8) 0 (0.0)
COPD 3(0.7) 1(0.4) 0 (0.0)
Laboratory findings
WBC count (cells/μL) 6850.6 ± 3617.4 7004.2 ± 3633.4 6175.2 ± 1765.9
Albumin (g/dL) 4.0 ± 1.6 3.9 ± 0.6 4.4 ± 0.4
Cholesterol (mg/dL) 160.4 ± 75.9 159.6 ± 97.9 197.9 ± 61.6
COPD chronic obstructive pulmonary disease, SD standard deviation, TB tuberculosis, WBC white blood cells
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When 234 KT recipients with donor QFT were evalu-
ated, 2 active TB cases were noted, one from a recipient
QFT (+)/donor QFT (−) pair and another from a recipient
QFT (−)/donor QFT (+) pair (Fig. 1b). The incidences of
TB in each situation are shown in Table 3.
The clinical characteristics of 3 patients with post-KT
TB are summarized in Table 4. All cases were living-
donor KT without desensitization, and post-KT times to
TB diagnosis were 38, 10, and 7 months after KT. One
patient had pulmonary TB, and 2 patients had extrapul-
monary TB.
The predictive ability of QuantiFERON for post-transplant
TB
We performed Poisson regression analysis to assess the
predictive ability of the QFT for post-KT TB development
(Table 5). The analysis of 446 recipients with QFT showed
that QFT positivity did not predict post-KT TB
Table 2 The association between Tuberculin skin test or QuantiFERON results and latent tuberculosis
QuantiFERON (n = 458) QuantiFERON (n = 138) TST≥ 10 mm (n = 138)
Positive Negative/indeterminate Positive Negative/indeterminate Positive Negative
Number (percent, %) 101 (22.1) 357 (77.9) 36 (26.1) 102 (73.9) 18 (13.0) 120 (87.0)
Abnormal chest radiography 10 (9.9) 7 (2.0)** 4 (11.1) 3 (2.9) 0 (0.0) 7 (5.8)
History of previous TB 10 (9.9) 11 (3.1)* 3 (8.3) 3 (2.9) 2 (11.1) 4 (2.9)
Clinical latent TB 6 (5.9) 6 (1.7)* 3 (8.3) 3 (2.9) 0 (0.0) 6 (5.0)
TB tuberculosis, TST tuberculin skin test
*P < 0.05, **P < 0.001 by Chi-square test
Fig. 1 The development of TB after KT. a Four hundred fifty-eight KT recipients who underwent a QFT. b Two hundred thirty-nine KT recipients
with a paired living donor with a QFT. KT, kidney transplantation; TB, tuberculosis; QFT, QuantiFERON-TB-Gold In-Tube test
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development (RR, 1.847; 95% CI, 0.168–20.373; P = 0.616).
When the 234 donor-recipient pairs were analyzed, nei-
ther recipient QFT positivity (RR, 5.012; 95% CI, 0.301–
83.430; P = 0.261) nor donor QFT positivity (RR, 1.758;
95% CI, 0.106–29.274; P = 0.694) could predict post-KT
TB development (Table 5).
Discussion
In this study, the QFT was positive in 22% of KT recipi-
ents, and recipient QFT positivity was associated with
clinically latent TB before KT. We showed that that the
incidence of post-KT TB was 0.242 cases/100 person-
years among 446 KT recipients at a median follow-up of
30.2 months and that neither recipient QFT positivity
nor donor QFT positivity could predict post-KT TB
development.
Consistent with previous reports [12, 13], the QFT
was significantly associated with latent TB, whereas the
TST showed no such association in patients with ESRD.
Moreover, agreement between the QFT and TST was
poor. Overall, our study demonstrated that the QFT is a
better diagnostic test for latent TB than TST in KT can-
didates. Treatment of latent TB is recommended for
solid organ transplant recipients with a positive TST or
IGRA result [2–4]. However, the actual benefit of this
practice is still unknown [2, 14]. IGRA yields a high rate
of false positives [15], and some TB breakthrough cases
developed despite isoniazid prophylaxis [16, 17]. More-
over, concerns about drug toxicity and resistance may
not justify routine isoniazid prophylaxis for recipients
with a positive IGRA result in a country with high-to-
intermediate TB burden, unless the predictive capacity
of IGRA for post-TB development is confirmed.
Several studies have been performed to validate the
diagnostic usefulness of the IGRA test for active TB.
Pooled sensitivity for active TB was 80% for the QFT
and 81% for the TB-specific ELISPOT assay (T-SPOT),
and pooled specificity of the QFT for active TB was 79
and 59% for T-SPOT [18]. However, the diagnostic per-
formance for extrapulmonary TB that is more common
in KT patients [19, 20] was slightly lower; pooled sensi-
tivity was 72% for the QFT and 90% for T-SPOT, and
Table 3 Tuberculosis incidence according to donor/recipient QuantiFERON status
Variables TB incidence rates
No. of patients No. of TB cases No. of person-years TB rate per 100,000 person-years 95% CI
Total patients 446 3 1238.7 242.2 49.9, 708.8
Positive QFT 95 1 277.6 360.2 9.1, 2007.1
Negative or indeterminate QFT 351 2 961.1 208.1 25.2, 751.7
Living donor-recipient pairs 234 2 551.8 362.5 43.9, 1309.3
Recipient QFT (+)/Donor QFT (+) 16 0 51.6 0 0, 7149.9
Recipient QFT (+)/Donor QFT (−) 20 1 48.2 2074.7 52.5, 11559.4
Recipient QFT (−)/Donor QFT (+) 57 1 134.9 741.3 18.8, 4130.2
Recipient QFT (−)/Donor QFT (−) 141 0 317.1 0 0, 1163.3
CI confidence interval, No number, QFT QuantiFERON test, TB tuberculosis
Table 4 Clinical characteristics of post-transplant tuberculosis cases
Case 1 Case 2 Case 3
Age range 40 - 50 40 - 50 40 - 50
Previous treatment (duration) Preemptive HD (4 months) HD (1 month)
LDKT or DDKT LDKT LDKT LDKT
Recipient QFT Negative Positive Negative
Donor QFT Positive Negative N/A
Recipient TST N/A N/A 0 mm
Desensitization No No No
Induction immunosuppression Basiliximab Basiliximab Basiliximab
Maintenance immunosuppression Steroid, tacrolimus, MMF Steroid, tacrolimus, MMF Steroid, tacrolimus, MMF
Time to TB diagnosis after KT 38 months 10 months 7 months
Type of TB TB lymphadenopathy TB colitis Pulmonary TB
F female, HD hemodialysis, KT kidney transplantation, LDKT living-donor kidney transplantation, M male, MMF mycophenolate mofetil, N/A, not applicable,
TB tuberculosis
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pooled specificity was 82% for the QFT and 68% for T-
SPOT [21]. IGRA also showed a good negative predict-
ive value (NPV) but a very poor positive predictive value
(PPV) for progression to active TB [2]. Pre-transplant T-
SPOT failed to show significant predictive potential for
post-transplant TB development [9]. In parallel, the PPV
and NPV of the QFT to predict TB in our results were
1.05 and 99.43%, respectively. Although the QFT seems
to be slightly more specific than T-SPOT, our results
showed that the QFT cannot sufficiently predict post-
transplant TB development. Taken together, we propose
using isoniazid prophylaxis for all patients with clinically
latent TB. Regarding the cases of positive IGRA without
evidence of clinically latent TB, routine isoniazid
prophylaxis may not be needed for KT patients in inter-
mediate to high TB-burden countries until we can obtain
contradictory evidence from large-scale, long-term
follow-up studies, due to a low PPV of IGRA for active
TB development and concerns about drug toxicity and
resistance.
Interestingly, two cases of TB developed in recipients
with negative QFT results. This suggested that the QFT,
just like T-SPOT, is not adequately sensitive in immuno-
suppressed hosts [9]. De novo post-KT TB infection can
also occur in countries with a high-to-intermediate TB
burden. Yet, latent TB in the donor may be transmitted
to the recipient after KT [22]. Actually, one case of TB
in a patient with a negative QFT result received kidneys
from a QFT-positive donor. Organ donation from do-
nors with active TB is generally contraindicated; how-
ever, there is some controversy concerning isoniazid
treatment for donors or recipients when the donor has
positive IGRA results. Some guidelines recommend
chemoprophylaxis for donors with a positive TST/IGRA
before donation [22]; however, it is challenging to treat
all donors with positive IGRA results for the same rea-
son as recipients. In our study, 31% of donors were QFT
positive, and the QFT of the donor could not predict the
development of TB. Although treatment of latent TB for
KT recipients with QFT-positive donors is recom-
mended in low TB-burden countries, routine treatment
is still controversial in high-to-intermediate TB-burden
countries, because drug toxicity and resistance may out-
weigh the benefits of treatment [22]. Further large-scale,
long-term follow-up studies are needed to confirm the
necessity of treatment based on donor QFT. Before con-
firmative evidence is available, a careful approach is
needed according to a center-specific policy, and we rec-
ommend close monitoring of KT patients with a positive
donor IGRA result without routine treatment in our
situation.
There were some limitations to our study. First, our
study was retrospective; therefore, the exact history of
contact with active TB patients was difficult to ascertain.
Second, the QFT or TST was not performed for all re-
cipients. The QFT was preferentially performed in adult
or living donor KT patients. However, when we analyzed
the incidence rate of post-KT TB in patients at our
center who did not undergo the QFT and in the study
population of the KNOW-KT [23], there was no signifi-
cant difference in the incidence rate between our study
population and either group. Next, the follow-up
duration was relatively short and the study population
was small for the adequate assessment of the predictive
usefulness of post-transplant TB development. Never-
theless, the present study is the first study to assess the
predictive potential of pre-KT QFT in recipients and
donors for post-KT TB development in an intermediate
TB-burden country. Larger scale studies with a long-
term follow-up are needed to verify our findings.
Conclusions
The QFT is more useful than the TST for diagnosing a
latent TB infection in KT candidates. However, the QFT
in both recipients and paired living donors may not
predict the short-term development of post-transplant
TB in an intermediate-TB-burden country.
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